• Entera Bio highlighted Phase 2 analyses of EB613, an oral osteoporosis drug candidate, at the ASBMR 2026 annual meeting.
• Results were already presented at the meeting, pointing to stronger bone-building effects in higher-risk women than in less severe patients.
• The update supports a shift toward an “anabolic-first” treatment approach, positioning EB613 as a potential alternative to daily injections.
• A registrational Phase 3 trial design was also presented, with a 12-month placebo-controlled study planned in about 900 postmenopausal women.
• The Phase 3 program targets registration based on bone density improvement, with a 24-month extension to assess longer-term safety and durability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entera Bio Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130700PRIMZONEFULLFEED9844576) on October 13, 2026, and is solely responsible for the information contained therein.